Emerging Stocks Down Under 6 September 2022: Medlab Clinical (ASX:MDC)

Medlab Clinical: Too many downside risks

Medlab Clinical (ASX: MDC) is one of the most unique biotechs on the ASX. It is rare to have a company that
has advanced a treatment to Phase 3 and even more so for a company that has a cannabis-based treatment,
but Medlab has done this. Still, it has not eliminated all uncertainty surrounding itself, including funding and a
potential listing on NASDAQ.


Click here to read the previous edition of Emerging Stocks Down Under published 30 August 2022.

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.